FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:LRRFIP2-RAP1A

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: LRRFIP2-RAP1A
FusionPDB ID: 50098
FusionGDB2.0 ID: 50098
HgeneTgene
Gene symbol

LRRFIP2

RAP1A

Gene ID

9209

5906

Gene nameLRR binding FLII interacting protein 2RAP1A, member of RAS oncogene family
SynonymsHUFI-2C21KG|G-22K|KREV-1|KREV1|RAP1|SMGP21
Cytomap

3p22.2

1p13.2

Type of geneprotein-codingprotein-coding
Descriptionleucine-rich repeat flightless-interacting protein 2LRR FLII-interacting protein 2leucine rich repeat (in FLII) interacting protein 2ras-related protein Rap-1AGTP-binding protein smg p21ARas-related protein Krev-1
Modification date2020031320200329
UniProtAcc

Q9Y608

Main function of 5'-partner protein: FUNCTION: May function as activator of the canonical Wnt signaling pathway, in association with DVL3, upstream of CTNNB1/beta-catenin. Positively regulates Toll-like receptor (TLR) signaling in response to agonist probably by competing with the negative FLII regulator for MYD88-binding. {ECO:0000269|PubMed:15677333, ECO:0000269|PubMed:19265123}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000336686, ENST00000354379, 
ENST00000396428, ENST00000421276, 
ENST00000421307, ENST00000440230, 
ENST00000490597, 
ENST00000494982, 
ENST00000356415, ENST00000369709, 
ENST00000436150, ENST00000545460, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score15 X 15 X 8=180010 X 9 X 4=360
# samples 1710
** MAII scorelog2(17/1800*10)=-3.40439025507934
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(10/360*10)=-1.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: LRRFIP2 [Title/Abstract] AND RAP1A [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: LRRFIP2 [Title/Abstract] AND RAP1A [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)LRRFIP2(37170553)-RAP1A(112245957), # samples:1
Anticipated loss of major functional domain due to fusion event.LRRFIP2-RAP1A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
LRRFIP2-RAP1A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
LRRFIP2-RAP1A seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
LRRFIP2-RAP1A seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
LRRFIP2-RAP1A seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
LRRFIP2-RAP1A seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneRAP1A

GO:0071320

cellular response to cAMP

21840392

TgeneRAP1A

GO:0072659

protein localization to plasma membrane

17916086

TgeneRAP1A

GO:0098696

regulation of neurotransmitter receptor localization to postsynaptic specialization membrane

12202034



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr3:37170553/chr1:112245957)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across LRRFIP2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across RAP1A (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000336686LRRFIP2chr337170553-ENST00000356415RAP1Achr1112245957+134225881629182
ENST00000336686LRRFIP2chr337170553-ENST00000436150RAP1Achr1112245957+170825881629182
ENST00000336686LRRFIP2chr337170553-ENST00000369709RAP1Achr1112245957+492025881629182
ENST00000336686LRRFIP2chr337170553-ENST00000545460RAP1Achr1112245957+71625881629182
ENST00000440230LRRFIP2chr337170553-ENST00000356415RAP1Achr1112245957+18747906131161182
ENST00000440230LRRFIP2chr337170553-ENST00000436150RAP1Achr1112245957+22407906131161182
ENST00000440230LRRFIP2chr337170553-ENST00000369709RAP1Achr1112245957+54527906131161182
ENST00000440230LRRFIP2chr337170553-ENST00000545460RAP1Achr1112245957+12487906131161182

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000336686ENST00000356415LRRFIP2chr337170553-RAP1Achr1112245957+0.0019383530.9980616
ENST00000336686ENST00000436150LRRFIP2chr337170553-RAP1Achr1112245957+0.0018217450.99817824
ENST00000336686ENST00000369709LRRFIP2chr337170553-RAP1Achr1112245957+0.0020598770.9979401
ENST00000336686ENST00000545460LRRFIP2chr337170553-RAP1Achr1112245957+0.0039157050.99608433
ENST00000440230ENST00000356415LRRFIP2chr337170553-RAP1Achr1112245957+0.0020913650.9979087
ENST00000440230ENST00000436150LRRFIP2chr337170553-RAP1Achr1112245957+0.0016096860.9983903
ENST00000440230ENST00000369709LRRFIP2chr337170553-RAP1Achr1112245957+0.0020862120.9979138
ENST00000440230ENST00000545460LRRFIP2chr337170553-RAP1Achr1112245957+0.0048110830.99518895

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for LRRFIP2-RAP1A

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
LRRFIP2chr337170553RAP1Achr111224595725859DIRMRELERQQKEEQFTAMRDLYMKN
LRRFIP2chr337170553RAP1Achr111224595779059DIRMRELERQQKEEQFTAMRDLYMKN

Top

Potential FusionNeoAntigen Information of LRRFIP2-RAP1A in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
LRRFIP2-RAP1A_37170553_112245957.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:13KEEQFTAM0.97440.91211119
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:03RQQKEEQF0.90830.8357816
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:01QKEEQFTAM0.99770.98661019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:24QKEEQFTAM0.99750.85931019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:13QKEEQFTAM0.99530.99291019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B14:02ERQQKEEQF0.95090.9591716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B14:01ERQQKEEQF0.95090.9591716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:10QKEEQFTAM0.88160.8021019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:37QKEEQFTAM0.82870.73091019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:18QKEEQFTAM0.78740.90351019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:06QQKEEQFTA0.76240.9656918
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B13:02QQKEEQFTA0.72550.9574918
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B50:01QQKEEQFTA0.70230.9204918
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B38:01ERQQKEEQF0.69940.9095716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B38:02ERQQKEEQF0.69260.9044716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:18ERQQKEEQF0.5820.5658716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:13QQKEEQFTA0.21790.9928918
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:01QQKEEQFTAM0.99990.8447919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:03QQKEEQFTAM0.95360.8504919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:25QQKEEQFTAM0.9460.9397919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B13:02RQQKEEQFTA0.6420.9187818
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B44:03EEQFTAMRDLY0.99980.92361223
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:06ERQQKEEQFTA0.99810.944718
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B48:01RQQKEEQFTAM0.99780.6944819
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B18:01EEQFTAMRDLY0.98950.73761223
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:08KEEQFTAM0.99140.83761119
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:09QKEEQFTAM0.99820.93081019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:12QKEEQFTAM0.99760.98721019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:05QKEEQFTAM0.99610.9851019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-C07:95ERQQKEEQF0.96840.5833716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:04QQKEEQFTA0.88560.9218918
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:12ERQQKEEQF0.79740.908716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B14:03QKEEQFTAM0.56170.92831019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B14:03ERQQKEEQF0.2810.9375716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:07QQKEEQFTAM0.99930.7389919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:04QQKEEQFTAM0.9990.8754919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:05QQKEEQFTAM0.87280.956919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B73:01ERQQKEEQFTA0.99870.9079718
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B40:04KEEQFTAM0.99940.70061119
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:54RQQKEEQF0.9940.8497816
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B41:03KEEQFTAM0.90870.59221119
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B48:02RQQKEEQF0.70250.9381816
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:31QKEEQFTAM0.99780.98631019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:02QKEEQFTAM0.99770.99291019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:09QKEEQFTAM0.92140.93761019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:11QKEEQFTAM0.81360.93041019
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B39:31ERQQKEEQF0.8030.9046716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:73QQKEEQFTA0.78570.9902918
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-C07:22ERQQKEEQF0.76380.6522716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B50:05QQKEEQFTA0.70230.9204918
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B50:04QQKEEQFTA0.70230.9204918
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B38:05ERQQKEEQF0.69940.9095716
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:135QQKEEQFTAM0.99990.8419919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:33QQKEEQFTAM0.99990.8447919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:27QQKEEQFTAM0.99990.8857919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:34QQKEEQFTAM0.99990.8447919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:125QQKEEQFTAM0.99990.8447919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:50QQKEEQFTAM0.99980.9291919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:53QQKEEQFTAM0.99960.8325919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:35QQKEEQFTAM0.99930.8416919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:68QQKEEQFTAM0.99920.6948919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:54QQKEEQFTAM0.99920.8171919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:73QQKEEQFTAM0.99530.9464919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:12QQKEEQFTAM0.99410.8941919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:30QQKEEQFTAM0.98880.9727919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:39QQKEEQFTAM0.94340.8751919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:20QQKEEQFTAM0.87290.9766919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B40:21QQKEEQFTAM0.81630.6766919
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B44:26EEQFTAMRDLY0.99980.92361223
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B44:13EEQFTAMRDLY0.99980.92361223
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B44:07EEQFTAMRDLY0.99980.92361223
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:73RQQKEEQFTAM0.99880.9688819
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B15:30RQQKEEQFTAM0.99750.9606819
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B18:11EEQFTAMRDLY0.99530.6821223
LRRFIP2-RAP1Achr337170553chr1112245957258HLA-B18:05EEQFTAMRDLY0.98950.73761223

Top

Potential FusionNeoAntigen Information of LRRFIP2-RAP1A in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
LRRFIP2-RAP1A_37170553_112245957.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-0407KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-0419KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-0431KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-0435KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-0438KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-0443KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-0447KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-0461KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-0482KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-0482QKEEQFTAMRDLYMK1025
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1216KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1527KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1534KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1601KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1602KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1603KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1604KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1605KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1607KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1608KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1609KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1610KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1611KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1612KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1614KEEQFTAMRDLYMKN1126
LRRFIP2-RAP1Achr337170553chr1112245957258DRB1-1616KEEQFTAMRDLYMKN1126

Top

Fusion breakpoint peptide structures of LRRFIP2-RAP1A

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4932LERQQKEEQFTAMRLRRFIP2RAP1Achr337170553chr1112245957258

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of LRRFIP2-RAP1A

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN4932LERQQKEEQFTAMR-7.9962-8.1096
HLA-B14:023BVN4932LERQQKEEQFTAMR-5.70842-6.74372
HLA-B52:013W394932LERQQKEEQFTAMR-6.83737-6.95077
HLA-B52:013W394932LERQQKEEQFTAMR-4.4836-5.5189
HLA-A11:014UQ24932LERQQKEEQFTAMR-10.0067-10.1201
HLA-A11:014UQ24932LERQQKEEQFTAMR-9.03915-10.0745
HLA-A24:025HGA4932LERQQKEEQFTAMR-6.56204-6.67544
HLA-A24:025HGA4932LERQQKEEQFTAMR-5.42271-6.45801
HLA-B44:053DX84932LERQQKEEQFTAMR-7.85648-8.89178
HLA-B44:053DX84932LERQQKEEQFTAMR-5.3978-5.5112
HLA-A02:016TDR4932LERQQKEEQFTAMR-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of LRRFIP2-RAP1A

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
LRRFIP2-RAP1Achr337170553chr11122459571019QKEEQFTAMCAAAAAGAGGAGCAATTTACAGCAATG
LRRFIP2-RAP1Achr337170553chr11122459571119KEEQFTAMAAAGAGGAGCAATTTACAGCAATG
LRRFIP2-RAP1Achr337170553chr11122459571223EEQFTAMRDLYGAGGAGCAATTTACAGCAATGAGGGATTTGTAT
LRRFIP2-RAP1Achr337170553chr1112245957716ERQQKEEQFGAACGACAACAAAAAGAGGAGCAATTT
LRRFIP2-RAP1Achr337170553chr1112245957718ERQQKEEQFTAGAACGACAACAAAAAGAGGAGCAATTTACAGCA
LRRFIP2-RAP1Achr337170553chr1112245957816RQQKEEQFCGACAACAAAAAGAGGAGCAATTT
LRRFIP2-RAP1Achr337170553chr1112245957818RQQKEEQFTACGACAACAAAAAGAGGAGCAATTTACAGCA
LRRFIP2-RAP1Achr337170553chr1112245957819RQQKEEQFTAMCGACAACAAAAAGAGGAGCAATTTACAGCAATG
LRRFIP2-RAP1Achr337170553chr1112245957918QQKEEQFTACAACAAAAAGAGGAGCAATTTACAGCA
LRRFIP2-RAP1Achr337170553chr1112245957919QQKEEQFTAMCAACAAAAAGAGGAGCAATTTACAGCAATG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
LRRFIP2-RAP1Achr337170553chr11122459571025QKEEQFTAMRDLYMKCAAAAAGAGGAGCAATTTACAGCAATGAGGGATTTGTATATGAAG
LRRFIP2-RAP1Achr337170553chr11122459571126KEEQFTAMRDLYMKNAAAGAGGAGCAATTTACAGCAATGAGGGATTTGTATATGAAGAAC

Top

Information of the samples that have these potential fusion neoantigens of LRRFIP2-RAP1A

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
Non-CancerLRRFIP2-RAP1Achr337170553ENST00000336686chr1112245957ENST00000356415TCGA-AF-3400-11A

Top

Potential target of CAR-T therapy development for LRRFIP2-RAP1A

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to LRRFIP2-RAP1A

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to LRRFIP2-RAP1A

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource